1
Abnormalities of hemoglobin and Glucose-6-Phosphate-
2
Dehydrogenase deficiency in children with uncomplicated
3
malaria and living in Banfora and Saponé, two different
4
malaria setting of Burkina Faso

5

6 .

7

8 **ABSTRACT**

Aims: The aim of this study is to assess the prevalence of hemoglobin abnormalities and G6PD deficiency and their respective influence on anemia occurring in less than five years old children with clinical *P. falciparum* malaria living in Burkina Faso.

Study design: The study was a cross-sectional survey with descriptive focus conducted from December 2010 to January 2013 in Saponé health district and from May to October 2011 in Banfora health district. Clinical and laboratory data were collected. Blood smears on slides for malaria diagnosis by microscopy, hemoglobin level and filter paper for the detection of human genetic factors were performed.

Methodology: A total of 386 subjects from Saponé (131) and Banfora (255) were enrolled. DNA collected from each sample was extracted using chelex-100 method and the human genetic resistance factors background was assessed by RFLP-PCR. Abnormal hemoglobin patients were classified as NonAA while AA was defined the normal hemoglobin

Results: In this study, 70.98% (274/386) were classified normal hemoglobin while 29.02% (112/386) of subjects were carrying at least one abnormal allele: 24.35%AC, 3.63% AS, 0.78%CC and 0.26%SC. G6PD deficiency was 9.59% (37/386) among which, 4.92% for male and 4.66% in female. However, this gender difference was not statistically significant (p=1.00). 319/367 (86.92%) of the patients were anemic (59.4% with moderate anemia and 20.98% with mild anemia). The prevalence of anemia in G6PD deficient subjects was 83.33% (of which 58.33% were moderate anemia and 22.22% middle anemia). The difference between types of hemoglobin (p=0.64) in the occurrence of anemia (AA 87.64% and Non AA 85.18%) was not statistically significant.

Conclusion: This study showed that the prevalence of these genetic factors was relatively low among children with clinical *falciparum* malaria with high parasite density. In addition, these factors appear to have no effect on anemia.

9 ***Keywords: Prevalence, hemoglobin, G6PD, children, malaria, Burkina Faso***

10

VIEW

1. INTRODUCTION

The incidence rate of malaria is estimated to have decreased by 21% between 2010 and 2015. The global tally of malaria in 2015 was 212 million new cases and 429,000 deaths [1]. Sub-Saharan Africa still accounts for a disproportionate share of the global burden of malaria with 90% of cases and 92% of deaths due to malaria [1]. Children under five years and pregnancy women represents the most affected targets [2]. Some genetic disorders are known to affect malaria development and the prevalence of disease such sickle cell disease (SCD), thalassemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and other red blood cell (RBC) genetic anemia [3].

About 5% of the worldwide population are healthy carriers of a sickle cell or thalassemic gene; with this figure reaching 25% in some regions [4] and more than 300,000 children with severe hemoglobinopathy are born every year [5]. Of all the hemoglobinopathies, the S-form or sickle-cell remains the most widespread. It mainly affects African and is currently present on several continents because of the populations migration. In Burkina Faso, the prevalence of the sickle cell trait varies from 8 to 10% [6,7]. Several authors have shown that heterozygous hemoglobinopathies (AS, AC) rarely have malaria [7]. These hemoglobinopathies also appear to confer protection against severe anemias [8,9]. Glucose-6-Phosphate Dehydrogenase (G6PD) which is an enzyme present in the cytoplasm of all cells in the body is involved in the first step of the metabolic pathway of pentose phosphates, thus producing NADPH [10]. The G6PD deficit affects more than 400 million people worldwide [11]. G6PD deficit represents the most frequent erythrocytic enzymopathy [12,13]. The global distribution of this enzymatic deficiency is particular and the highest frequencies are observed in hyper-endemic malaria setting [14]. In Burkina Faso, the prevalence of G6PD deficiency is estimated between 8 to 9% [6]. Previous studies (in vitro or in vivo) were carried out to characterize on molecular, biochemical and cellular basis the mechanism that could underlie the protection of the G6PD deficient subject against malaria [15,16]. Then, both hemoglobin abnormality and G6PD deficiency seem to confer protection against malaria and prevent anemia [17].

The aim of this study is to assess the distribution of beta-globin abnormalities and G6PD deficiency and their influence on the prevalence of anemia in children with *Plasmodium falciparum* malaria and living in two different malaria-endemic areas in Burkina Faso. This will provide data on the prevalence of these two abnormalities in a population with uncomplicated malaria in Burkina Faso.

2. METHODOLOGY

2.1 Study sites

The study was conducted in two areas covering the health district of Banfora and Saponé. Banfora health district in the Comoé province is located in southwestern part of Burkina Faso, at about 450 km from Ouagadougou, the capital city of Burkina Faso, where malaria is endemic. Malaria transmission in that area is permanent with seasonal peaks during the rainy season from May to November. The health district of Saponé is located 50 Km south-west of Ouagadougou. In this area malaria transmission even seasonal

UNDER PEER REVIEW

47 is short compared to the one of Banfora health district (June to October). According to the Ministry Health,
48 in Burkina Faso malaria incidence was 364‰ in 2010 and 413‰ in 2013 [18,19].

49 **2.2 Study Population, design and period**

50 A total of 386 children aged between 6 to 59 months were recruited. It was cross-sectional surveys with
51 descriptive focus conducted from December 2010 to January 2013 in Saponé health district and from May
52 to October 2011 in Banfora health district. The study was part of a clinical trial study, assessing the
53 efficacy of two Artemisinin combination therapies (ACT). The inclusion criteria were as followed : 1) fever
54 (axillary temperature ≥ 37.5°C) and/or a history of fever within the past 48 hours; 2) asexual *P. falciparum*
55 mono-infection identified microscopically on blood smears with parasite density between 2000 and 200000
56 parasites/µl of blood; 3) no history of anti-malarial drug administration in the last two weeks; 4) no history
57 of serious adverse effects to the study drugs (mefloquine, quinine, artesunate, chloroquine and
58 sulphadoxine-pyrimethamine); 6) no evidence of a concomitant febrile illness; 7) no sign/symptoms of
59 severe malaria as defined by WHO.

60 **2.3 Ethical considerations**

61 The study received approval from the Ethics Committee for Health of Burkina Faso before its
62 implementation (DELIBERATION $N^0$2011-9-59). It was conducted in accordance with good clinical and
63 laboratory practice. In addition, written informed consent was obtained from the parents or guardians of all
64 participating children before enrolment. Confidentiality of information was ensured by assigning
65 identification numbers to subjects.

66 **2.4 Samples collection**

67 For each subject included in this study, physical examination, capillary blood samples on slides, venous
68 blood samples (1mL) and filter papers were collected. Slides were used for the diagnosis of malaria
69 parasites, venous blood samples for hemoglobin concentration and the filter papers for the analysis of
70 human genetic factors.

71 **2.5 Malaria diagnosis by microscopy**

72 After making the thick and thin blood smears, the slides were air-dried. The thick and thin blood films were
73 stained with Giemsa 6% for 35 min. The parasites were counted against 200 leukocytes and then
74 extrapolated to parasites per microliter of blood. At least one hundred power film fields were examined
75 before assigning a negative malaria diagnosis. The number of parasites per microliter of blood was
76 calculated using the last full blood count of the patient or the theoretical value of 8000 leucocytes/µl. The
77 Parasite Density (PD) was estimated using the following formula:

78 PD = N x 8000/X

79 With N = number of parasites counted and X = number of counted leucocytes or the value of the full blood
80 count.

UNDER PEER REVIEW

81 Two experts microscopists who read each blood slide were blinded from each other's reading. All
82 discordant readings were re-read by a third microscopist who was blinded from the previous results.

83 **2.6 Hemoglobin concentration**

84 Hemoglobin levels were determined using an ABX Pentra 60 hematology analyzer (HORIBA ABX SAS,
85 France) according to the CNRFP SOP. Daily internal quality controls were followed as quality measures
86 [20]. Analysis of samples was performed within 8 hours of blood draw.

87 **2.7 Blood spots samples and DNA extraction**

88 Blood from finger prick spotted onto Whatman filter Papers (Whatman 3 mm, GE Healthcare, Pittsburg,
89 USA), was labeled with patients' study numbers, air-dried, and individually placed into plastic bag marked
90 and containing a desiccant to protect against humidity. The bags were stored at room temperature until
91 DNA extraction. Parasite DNA was extracted using Chelex methods [21]. Briefly, three pieces of filter
92 paper was soaked overnight in a solution of 10% saponin in PBS and was subsequently washed in PBS.
93 Thus, 50 µl of 20% Chelex® 100 solution (Bio-Rad Laboratories) were added to 1.5 ml microcentrifuge
94 tube containing 3 fragments of filter paper sample. Then, 100 µl of sterile water were added and the
95 microcentrifuge tube placed onto a heating block at 95-100°C for 10 minutes of incubation. During the
96 incubation phase, the tube was gently whirled and returned to the heat block every two minutes. The
97 samples were centrifuged twice and the final supernatant about 150 µl was conserved in a new labeled
98 tube and stored at -20°C until it was used for the amplification reaction.

99 **2.8 Human genetic factors genotyping**

100 **2.8.1 Hemoglobin genotyping**

101 The hemoglobin in the β-chain of the globin gene at codon six was determined by using polymerase chain
102 reaction-restriction fragment length polymorphism (PCR-RFLP). The PCR conditions were as follows: one
103 (1) cycle of 5 min at 96°C, 30 cycles of 96°C for 30 secs, 60°C for 1 min, 72°C for 30 secs and 72°C for 7
104 min. DNA samples were amplified. The expected fragment length was 358 bases pairs (bp). The fragment
105 obtained was digested for three hours at 37°C with MnlI for discrimination between HbAA (173 bp, 109 bp,
106 and 60 bp), HbSS/HbCC and HbSC (173 bp, 109 bp, and 76 bp), HbAS/HbAC (173 bp, 109 bp, 76 bp and
107 60 bp). A second digestion with DdeI allowed for further discrimination for ambiguous results between
108 HbSS (331 bp), HbCC (201 bp and 130 bp), HbSC (130 bp, 201 bp and 331 bp), HbAS (130 bp, 201 bp
109 and 331 bp) and HbAC (201 bp and 130 bp). PCR products were analyzed by electrophoresis in a 1.5 %
110 agarose gel.

111 **2.8.2 G6PD genotyping**

112 DNA was amplified and analyzed for the presence or absence of one of the common G6PD mutations
113 G→A 202 using Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)
114 method. PCR amplification was done using primers forward and reverse (Table 1). Details of the PCR-
115 RFLP process are described elsewhere [22].

UNDER PEER REVIEW

Table 1. Primers sequences for hemoglobin type and G6PD amplification

Genes	Primer name	Allelic-specific primers
Hemoglobin type	Forward	AGGAGCAGGGAGGGCAGGA
	Reverse	TCCAAGGGTAGACCACCAGC
G6PD type	Forward	GTGGCTGTTCCGGGATGGCCTTCG
	Reverse	CTTGAAGAAGGGCTCACTCTGTTTG

2.9 Statistical Analysis

Double entry of data in Excel 2010 was performed and analyzed using R version 3.5.1 (2018-07-02). The statistical tests done based on Pearson chi-square for the comparison of proportions and frequencies or the Fisher test for the comparison of proportions when the theoretical number is less than 5; the Student test for comparison of means. P values were reported, with differences considered significant at $p < .05$.

First, we determined the prevalence of hemoglobin and G6PD type in the study area. After we compared *P. falciparum* parasite density between normal subjects and those with abnormality. Then we analyzed the link between human genetic factors and anemia.

3. Results

3.1 Socio-demographic characteristics

A total of 386 subjects were enrolled, of whom 190 (49.22%) were male and 196 (50.78%) female. There is no predominance by gender ($p = 0.72$). The sex ratio M/F is 0.97. The majority of the population was 12-23 months old and 24-35 months old (28.50% and 27.20% respectively). On the other hand, children aged 6-11 months were the least represented, with 12.43%. The mean age was 28.87 ± 1.44 months.

3.2 Prevalence of human genetic factors

The table 2 compares within each group the genotypic frequency observed with that expected from the calculated allelic frequencies. The study population follows the Hardy-Weinberg equilibrium

Table 2. Genotypic frequencies of hemoglobin type

Genotype		Theoretical number	Theoretical frequency (%)	Observed Number	Observed frequency (%)	p	IC (95%)
AA		278	71,65	274	70,98	0,90	[66,13-75,41]
Non AA		110	28,35	112	29,02	0,90	[24,59-33,87]
	AC	85	21,90	94	24,35	0,47	[20,22-29,01]
Non AA	AS	15	3,86	14	3,63	1,00	[2,08- 6,15]
	CC	7	0,43	3	1,80	0,34	[0,20-2,45]
	SC	2	0,51	1	0,26	1,00	[0,01-1,66]

UNDER PEER REVIEW

All	388	100,00	386	100,00	0,47	[98,77-100,00]

The prevalence of the normal hemoglobin type was higher than abnormal type (p<0.001). Overall, 274 (70.98%) children did not have abnormal hemoglobin type and 94 (24.35%) were HbAC carriers. Hemoglobin types were similar among sites (Table 3).

Table 3. Distribution of subjects by hemoglobin type

Hemoglobin type	Site			All
	Banfora	Saponé	p-value	
HbAA (n) (%)	100 (76.34%)	174 (68.23)	0.12	274 (70.98%)
HbAC (n) (%)	30 (22.90%)	64 (25.10)	0.72	94 (24.35%)
HbAS (n) (%)	1 (0.76%)	13 (5.10%)	0.06	14 (3.63%)
HbCC (n) (%)	0 (0.0)	3 (1.18%)	0.52	3 (0.78%)
HbSC (n) (%)	0 (0.0)	1 (0.39%)	1.00	1 (0.26%)
Total (n) (%)	131 (33.94%)	255 (66.06%)	NS	386 (100.00%)

The estimated prevalence of G6PD deficiency frequency (Table 4) in our population was 9.59% (37/386), with a statistically significant difference between G6PD Deficient and G6PD Normal (P<0.001).

Table 4. Distribution of subjects by G6PD type

Parameters	G6PD type			All
	G6PD Deficient	G6PD Normal	p-value	
Frequency (n) (%)	37 (9.59%)	349 (90.41%)	<0.001	386 (100.0%)
Male (n) (%)	19 (10.00%)	171 (90.00%)	<0.001	190 (49.22%)
Female (n) (%)	18 (9.18%)	178 (90.82%)	<0.001	196 (50.78%)

3.3 Human genetic factors and *P. falciparum* parasite

There was no significant difference in the *P. falciparum* parasite means densities between hemoglobin and G6PD types (p=0.94 and p=0.87 respectively). However, the results showed (Table 5) significant difference in the means of gametocytes density Hemoglobin genotypes carriers (p<0.001).

Table 5. Distribution of subjects by human genetic factors, gametocyte carriage and *P. falciparum* parasite density

Parameters		**Gametocyte carriage(n) (%)**	**Parasite density (parasites/µl) 95% confidence interval (CI)**
Hemoglobin type	HbAA (274)	22 (8.03%)	52167.93 [46745.80-57590.06]
	HbAC (94)	10 (10.64%)	47075.59 [38666.80-55484.37]
	HbAS (14)	3 (21.43%)	50084.64 [19602.83-80566.45]

UNDER PEER REVIEW

	HbCC (3)	1 (33.33%)	31527.67 [-33535.00-96590.34]
	HbSC (1)	1 (100.0%)	14081.00 NS
	p-value	0.005	0.94
G6PD type	Deficient (37)	4 (10.81%)	50407.26 [45722.75-55091.76]
	Normal (349)	33 (9.45%)	52346.89 [36934.72-67759.06]
	p-value	1.00	0.87
	All (386)	37 (9.58%)	50593.18 [46129.26-55057.09]

Note: HbAA: homozygous wild type genotype, HbAS: heterozygote sickle cell hemoglobin, HbAC: heterozygote hemoglobin C, HbSC: heterozygote hemoglobin S and C, HbCC: homozygote hemoglobin C.

3.4 Human genetic factors and anemia

Anemia types were classified following that of the WHO definition. The different ranges are: Normal >11g/dl; Middle 10-10.9g/dl; Moderate 7-9.9g/dl; Severe <7g/dl. The mean values of hemoglobin rate permit us to have all subjects' groups (when the population was subdivided by human genetic factors) with a moderate anemia (Fig.1.).



Fig. 1. Mean hemoglobin rate by human genetic factors

Note: HbAA: homozygous wild type genotype, HbAS: heterozygote sickle cell hemoglobin, HbAC: heterozygote hemoglobin C, HbSC: heterozygote hemoglobin S and C, HbCC: homozygote hemoglobin C.

The prevalence of anemia was 87.64% (227/259) and 85.18% (92/108) in subjects with normal and abnormal hemoglobin, respectively. For subjects with G6PD deficiency, a total of 83.33% (30/36) were

UNDER PEER REVIEW

182 anemic or 58.33% (21/36) had moderate anemia and 22.22% (8/36) middle anemia (Table.6). After
183 analysis of anemia type, there were no differences (p>0.05) between normal subjects and those with
184 abnormality (G6PD deficiency and abnormal hemoglobin).

185 **Table.6. Anemia type in the population by human genetics factors**

Parameters	Hemoglobin type				G6PD type		
	All (367)	AA (259)	NonAA (108)	p-value	Normal (331)	Deficient (36)	p-value
Normal n(%)	48 (13.08%)	32 (12.35%)	16 (14.81%)	0.64	42 (12.69%)	6 (16.67%)	0.68
Mild n(%)	77(20.98%)	61 (23.55%)	16 (14.81%)	0.08	69 (20.84%)	8 (22.22%)	1.00
Moderate n(%)	218 (59.40%)	146 (56.37%)	72 (66.67%)	0.08	197 (59.52%)	21 (58.33%)	1.00
Severe n(%)	24 (6.54%)	20 (7.72%)	4 (3.70%)	0.24	23 (6.95%)	1 (2.78%)	0.54

186

187 *AA: homozygous wild type genotype, NonAA: Abnormal hemoglobin (HbAC, HbAS, HbCC, HbSC), Deficient: G6PD*
188 *Deficient and Normal: G6PD normal*

189

190 4. Discussion

191 Children aged 6 -11 months are the least represented in our study population. Born from mothers living in
192 high transmission areas, the study population have a certain level of clinical and parasitological immunity
193 for a period of 3 to 6 months after birth. A study in older children confirmed the protective effect of passive
194 transfer of antibodies [23].

195 In this study, 29.02 % of subjects had hemoglobinopathy. A higher frequency of AC hemoglobin
196 carriers (24.35%) had been obtained in our population compared to that identified in Mali (13%) by
197 Travassos in 2015 [24]. This could be explained by the fact that hemoglobin C has a maximum frequency
198 in Burkina Faso [25]. The prevalence of hemoglobin AS 3.63 % is low to findings already reported in
199 Ghana (9.10%) in 2014 [26] and in Burkina Faso (8.07%) in 2015 [27]. No homozygous SS was met in our
200 study but the prevalence of hemoglobin S was low. These low rates may be due to our sampling or to the
201 fact that sickling is a hindrance to parasite development. This prevalence is comparable to that reported
202 by Modiano et al in 2001 in malaria infected population.

203 The prevalence of G6PD deficient subjects in our population was low. This frequency could be
204 explained not only by sampling but also by the fact that the relatively high parasitemia (>2000 parasites)
205 cause us to lose positive subjects. Malaria Atlas Project data show a prevalence of G6PD deficiency in
206 Burkina Faso which is 9.38% [5.6-15]. Similar studies in other regions give lower or higher frequencies.
207 Carter in 2011 found frequencies of 17.4% in Ghana and 19.7% in Mali [28]. A prevalence of 15.8% was
208 found in Tanzania [29]. In our study, there were no distribution of G6PD deficiency according to the sex.
209 This is in contrast with previous studies where high prevalence's among men were found. Ouattara and
210 colleagues in 2014 had a male prevalence of 14.3% and 6.0% among women [30].

211 Normal hemoglobin carriers (AA) have a higher parasitic density than carriers of abnormal
212 hemoglobin. The mechanisms by which the HbS trait protects against *P. falciparum* are still only partially

UNDER PEER REVIEW

213 understood, but the implication of two factors seems to dominate [25]. The first line of defense is the
214 acceleration of the falciformation of the parasitized cells, which facilitates their withdrawal from the
215 circulation. The parasites which have escaped this process then see their growth hampered when the host
216 cell is subjected to hypoxia and adheres to the endothelium of the venules. Several authors have shown
217 that heterozygous sickle cells and AC carriers rarely have malaria attacks [6,7] and low parasitaemias [6].
218 Among subjects with abnormal hemoglobin, AS subjects have a higher parasitaemia. All subjects with
219 hemoglobin CC and SC had the lower parasitaemia. This is consistent with the in-vitro tests that
220 demonstrate that *Plasmodium* develops poorly in HbCC erythrocytes. Indeed, studies carried out in vitro
221 on oxygenated CC cells have produced the following results [31]: invasion by the parasite is normal; the
222 first growth cycle is normal, but the number of ring forms is substantially reduced after the schizont stage,
223 schizonts are seen to degenerate on the fourth day; in comparison with normal parasitic cells, resistance
224 to osmotic lysis is increased. These cells have trouble breaking and releasing merozoites in a normal
225 manner.

226 The highest parasitic density is observed in G6PD normal subjects. This difference was not
227 statistically significant ($p = 0.87$). One might think that the intra-erythrocytic replication of *P. falciparum* is
228 not affected by the existence of a G6PD deficiency. Studies have shown that parasitic density does not
229 differ as a function of G6PD status. Martin's work in 1994 had questioned the hypothesis that G6PD
230 deficiency would greatly impede the development of the parasite [32]. Indeed, *in vitro*, it has shown that
231 the parasite develops well in G6PD deficient erythrocytes in the absence of oxidative stress.

232 The gametocyte index obtained in our study was lower (9.58%) than that obtained in Uganda by Bwayo
233 (22.0%) in 2014 [10] in children aged from six months to nine years and in Burkina Faso by Bougouma
234 (30.5%) in 2012 [6] with children under five years. This may be due to the several efforts made since 2005
235 including provision of artemisinin-based combinations treatments (ACTs), distribution of long-lasting
236 insecticidal nets (LLINs) and scale-up of seasonal malaria chemoprevention with amodiaquine-
237 sulfadoxine-pyrimethamine (AQ-SP) in children aged between 6 to 59 months [33].

238 A moderate anemia has been observed in all hemoglobin type group. However, Diop in Senegal
239 [34] with subjects aged 3 to 53 years had AS subjects with normal hemoglobin and SC subjects with mild
240 anemia. The majority of G6PD deficient subjects were anemic. This may suggest that the G6PD
241 deficiency is an anemic factor. It should be noted that G6PD plays an important role in the maturation of
242 erythroids [35]. In 2008, in a study by Capelli with G6PD deficient subjects showed that, in the absence of
243 hemolytic seizures and triggering factors, G6PD deficiency was not related to anemia or hemoglobin [36].
244 After analyzing of these human genetic factors effect, malaria infection has probably a bigger role on the
245 malaria level in our study (we have an average of repeated infestation with *Plasmodium* of 2-3
246 episodes/year of malaria per child under 5 years of age). Also**,** malnutrition and iron deficiency that affects
247 these children from lower socioeconomic classes may be the cause of the different types of anemia
248 encountered in this study. However, other nutritional deficiencies (folic acid, vitamin B12 and vitamin A),
249 acute or chronic inflammation, and parasitic infections can also cause anemia.
250

UNDER PEER REVIEW

5. Conclusion

In our study the prevalence of abnormal hemoglobin and G6PD is relatively low, probably because of study population specified by a high parasite density. In addition, G6PD deficiency does not appear to influence parasitaemia or to be associated with the occurrence of anemia. The abnormality of hemoglobin, although influencing parasitaemia, does not seem to have any effect.

Competing interests

Authors have declared that no competing interests exist

Consent

All authors declare that written informed consent was obtained from the patient (or other approved parties) for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial Board members of this journal.

References

1. WHO World Health Organization. Summary. 2016 183p
2. Breman JG, Egan A, GT K The intolerable burden of malaria: a new look at the numbers. American Society of Tropical Medicine and Hygiene 2001 1824-1907
3. Vitor R. R. de Mendonça, Marilda Souza Goncalves, Barral-Netto M The Host Genetic Diversity in Malaria Infection. Journal of Tropical Medicine 2012 (2012): 17
4. Moormann AM, Embury PE, Opondo J, Sumba O, Ouma J Frequencies of sickle cell trait and glucose-6-phosphate dehydrogenase deficiency differ in highland and nearby lowland malariaendemic areas of Kenya. Transactions of the Royal Society of Tropical Medecine and Hygiene 2003 (97): 513-514
5. Williams TN, Weatherall DJ World distribution, population genetics, and health burdens of the hemoglobinopathies. Cold Spring Harb Perspect Med 2012 9 (2):
6. Bougouma EC, Tiono AB, Ouedraogo A, Soulama I, Diarra A, et al. Haemoglobin variants and *Plasmodium falciparum* malaria in children under five years of age living in a high and seasonal malaria transmission area of Burkina Faso. Malar J 2012 (11): 154
7. Modiano D, Sirima BS, Konate A, Sanou I, Sawadogo A Leucocytosis in severe malaria. Trans R Soc Trop Med Hyg 2001 2 (95): 175-176
8. Diallo DA, Doumbo OK, Dicko A, Guindo A, Coulibaly D, et al. A comparison of anemia in hemoglobin C and normal hemoglobin A children with Plasmodium falciparum malaria. Acta Trop 2004 3 (90): 295-299
9. Mockenhaupt FP, Mandelkow J, Till H, Ehrhardt S, Eggelte T, et al. Reduced prevalence of Plasmodium falciparum infection and of concomitant anaemia in pregnant women with heterozygous G6PD deficiency. Trop Med Int Health 2003 2 (8): 118-124
10. Bwayo D, Kaddumukasa M, Ddungu H, Kironde F Prevalence of G-6-Phosphate Deshydrogenase deficiency and its association with Plasmodium falciparum inection among children in Iganga distric in Uganda. BMC Research notes 2014 (7): 372
11. Beutler E Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 2008 (111): 16-24
12. Sarah A. Tishkoff, Robert Varkonyi, Nelie Cahinhinan, Salem Abbes, George Argyropoulos, et al. Haplotype Diversity and Linkage. Desiquilibrium at Human G6PD: Recent Origin of alleles that confer malarial resistance. Science 2001 (293): 455-462

UNDER PEER REVIEW

297 13. Sridevi S, Roshan C, Dipika M G6PD gene mutation in India producting drug-induced haemolytic
298 anaemia. British Journal of Haematology 2002 (116): 671-672
299 14. Badens C, Martinez Di Montemuros F, Thuret I, Michel G, Mattei JF, et al. Molecular basis of
300 haemoglobinopathies and G6PD deficiency in the Comorian population. The hematology Journal
301 2000 (1): 264-268
302 15. Beutler E, Robson M, Buttenwiesen E The mecanism of glutathion destruction and protection in drug
303 sensitive and no sensitive erythrocytes : in vitro studies. Clin Invest 1957 (36): 617-628
304 16. Sodeinde O Glucose-6-phosphate dehydrogenase deficiency. Balliers Clin Hematol 1992 (5): 367-382
305 17. Mégarbane B Déficit en glucose-6-phosphate déshydrogénase : quand y penser et quelles
306 précautions prendre ? . Elsevier 2008 17 399-406
307 18. DGISS Direction Générale de l'Information et des Statistiques Sanitaires/Ministère de la Santé, 2011,
308 Ouagadougou. Tableau de bord Santé 2010. pp. 80.
309 19. DGESS (2014) Direction Générale des Etudes et des Statistiques Sectorielles/Ministère de la Santé,
310 Ouagadougou. Tableau de bord 2013 des Indicateurs de Santé. pp. 94.
311 20. Dosoo DK, Kayan K, Adu-Gyasi D, Kwara E, Ocran J, et al. Haematological and Biochemical
312 Reference Values for Healthy Adults in the Middle Belt of Ghana. PLoS One 2012 4 (7):
313 21. Plowe CV, Djimde A, Bouare M, Doumbo O, WelllemsTE Pyrimethamine and proguanil resistance-
314 conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain
315 reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995 (52): 565-568
316 22. Bwayo D, Kaddumukasa M, Ddungu H, Kironde F Prevalence of glucose-6-phosphate dehydrogenase
317 deficiency and its association with *Plasmodium falciparum* infection among children in Iganga
318 distric in Uganda. BMC Research notes 2014 7 372-376
319 23. Arunee Sabchareon, Thierry Burnouf, Daniel Ouattara, Phanorsi Attanath, Hasnaa Bouharoun-
320 Tayoun, et al. Parasitologic and clinical human response to immunoglobulin administration in
321 Falciparum malaria. American Journal of Tropical Medecine and Hygiene 1991 (45): 297-308
322 24. Travassos MA, Coulibaly D, Laurens MB, Dembélé A, Tolo Y, et al. Hemoglobin C trait provides
323 protection from clinical Falciparum malaria in Malian children. Journal of Infectious Diseases 2015
324 (308): 1778-1786
325 25. Nagel RL, Labie D La résistance innée au paludisme due aux anomalies de l'hémoglobine.
326 Hématologie 2002 (8): 405 -413
327 26. Amoako N, Asante KP, Adjei G, Awandare GA, Bimi L, et al. Associations between red cell
328 polymorphisms and Plasmodium falciparum infection in the middle belt of Ghana. PLoS One 2014
329 12 (9): e112868
330 27. Valentina D. Mangano, Youssouf Kabore, Edith C. Bougouma, Federica Verra, Nuno Sepulveda, et al.
331 Novel Insights Into the Protective Role of Hemoglobin S and C Against Plasmodium falciparum
332 Parasitemia The Journal of Infectious Diseases 2015 4 (212): 625-634
333 28. Carter N, Pamba A, Duparc S, Waitumbi JN Frequency of glucose-6-phosphate dehydrogenase
334 deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial
335 clinical trials. Malar J 2011 (10): 241-254
336 29. Enevold A, Lusingu JP, Mmbando B, Alifrangis M, Lemnge M, et al. Reduced Risk of Uncomplicated
337 Malaria Episodes in Children with Alpha+-Thalassemia in Northeastern Tanzania. American
338 Journal of Tropical Medecine and Hygiene 2008 (78): 714-720
339 30. Ouattara A, Bisseye C, Bazie B, Diarra B, Compaore T, et al. Glucose-6-phosphate dehydrogenase
340 (G6PD) deficiency is associated with asymptomatic malaria in a rural community in Burkina Faso.
341 Asian Pacific Journal of Tropical Biomedicine 2014 8 (4): 655-658
342 31. Olson JA, Nagel RL Synchronized cultures of *P. falciparum* in abnormal red cells: The mechanism of
343 the inhibition of growth in HbCC cells. blood 1986 (67): 997-1000.
344 32. Usanga EA, Luzzatto L Adaptation of Plasmodium falciparum to glucose 6-phosphate dehydrogenase-
345 deficient host red cells by production of parasite-encoded enzyme. Nature 1985 (313): 793-795
346 33. Somé AF, Bazié T, Zongo I, Yerbanga RS, Nikiéma F, et al. *Plasmodium falciparum* msp1 and msp2
347 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in
348 Bobo-Dioulasso, Burkina Faso Parasites and Vectors 2018 (11): 323-330
349 34. Diop S, Thiam D, Sene A, Cissé M, Fall K, et al. Prevalence of G6PD deficiency in sickle cell disease
350 patients in Dakar. Med Afr Noire 2000 7 (47): 322-326

UNDER PEER REVIEW

351 35. Nouraie M, Reading NS, Campbell A, Minniti CP, Rana SR, et al. Association of G6PD with lower
352 haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. Br J
353 Haematol 2010 2 (150): 218-225
354 36. Capelli MD Anémie par déficit en G6PD. Lancet 2008 (371): 64-74
355
356
357

UNDER PEER REVIEW